Marc Siegel, MD

Most Recent Articles by Marc Siegel, MD

Antidote: Copper and Dementia

Antidote: Copper and Dementia

A new study about copper's role as a possible contributing factor in the development of Alzeheimer's Disease has come in just below the media radar, despite its obvious importance

Antidote:E-Cigarettes

Antidote:E-Cigarettes

E-cigarettes, battery-operated devices which provide nicotine vapor, are a promising tool to help people stop smoking

Antidote: On cancer and CD47

Antidote: On cancer and CD47

CD47 is one story that the media may have gotten right.

Antidote: Zithromax

Antidote: Zithromax

The media's hyperbolic reaction to an FDA warning on Zithromax manages to both unduly frighten patients and skirt the real problem—the overuse of antibiotics

On Flu Vaccine and the Elderly

On Flu Vaccine and the Elderly

The news from the CDC that this year's flu vaccine appears to be less than 60 percent effective at preventing severe flu symptoms, and only 9 percent with the elderly, has stirred the pot in the direction of denigrating what is still a useful vaccine.

More Articles by Marc Siegel, MD

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.